References
- CDC. CDC Tracks New SARS-CoV-2 Variant, BA.2.87.1. 2024 [cited; Available from: https://www.cdc.gov/ncird/whats-new/covid-19-variant-update-2024-02-09.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Frespiratory-viruses%2Fwhats-new%2Fcovid-19-variant-update-2024-02-09.html.
- Khare S, Gurry C, Freitas L, et al. Gisaid's role in pandemic response. China CDC Wkly. 2021 Dec 3;3(49):1049–1051.
- Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Feb 10.
- Cerutti G, Guo Y, Zhou T, et al. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1. Cell Host Microbe. 2024;13(5):819–33 e7. doi:10.1016/j.chom.2021.03.005
- Kubik S, Arrigo N, Bonet J, et al. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. Viruses. 2024;9(11.
- Zhang L, Dopfer-Jablonka A, Nehlmeier I, et al. Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage. Vaccines (Basel). 2024;12(5):487, doi:10.3390/vaccines12050487
- Lasrado N, Rössler A, Rowe M, et al. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1. Vaccine. 2024/03/07/.
- Yang S, Yu Y, Jian F, et al. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1. Emerg Microbes Infect. 2024 Dec;13(1):2343909, doi:10.1080/22221751.2024.2343909
- Wang X, Jiang S, Ma W, et al. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies. Signal Transduct Target Ther. 2024 May 9;9(1):123, doi:10.1038/s41392-024-01849-6